272 related articles for article (PubMed ID: 37503323)
1. Circadian rhythm as a key player in cancer progression as well as a therapeutic target in
Wang S; Khan S; Nabi G; Li HY
Front Oncol; 2023; 13():1240676. PubMed ID: 37503323
[TBL] [Abstract][Full Text] [Related]
2. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.
Wang J; Huang Q; Hu X; Zhang S; Jiang Y; Yao G; Hu K; Xu X; Liang B; Wu Q; Ma Z; Wang Y; Wang C; Wu Z; Rong X; Liao W; Shi M
Cancer Res; 2022 Apr; 82(8):1503-1517. PubMed ID: 35255118
[TBL] [Abstract][Full Text] [Related]
3. Loss of circadian clock gene expression is associated with tumor progression in breast cancer.
Cadenas C; van de Sandt L; Edlund K; Lohr M; Hellwig B; Marchan R; Schmidt M; Rahnenführer J; Oster H; Hengstler JG
Cell Cycle; 2014; 13(20):3282-91. PubMed ID: 25485508
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
[TBL] [Abstract][Full Text] [Related]
5. Challenges and future of HER2-positive gastric cancer therapy.
Ma C; Wang X; Guo J; Yang B; Li Y
Front Oncol; 2023; 13():1080990. PubMed ID: 36793592
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
7. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
8. Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance.
Mitani S; Kawakami H
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050652
[TBL] [Abstract][Full Text] [Related]
9. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.
Jiao XD; Liu K; Wu Y; Zhou XC; Qin BD; Ling Y; Liu J; He X; Du H; Xiang J; Zang YS
Oncologist; 2021 Sep; 26(9):717-721. PubMed ID: 33896090
[TBL] [Abstract][Full Text] [Related]
10. Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.
Narita Y; Kadowaki S; Masuishi T; Taniguchi H; Takahari D; Ura T; Ando M; Tajika M; Niwa Y; Eto T; Hara H; Asayama M; Yamaguchi K; Yatabe Y; Muro K
Oncol Lett; 2017 Aug; 14(2):2545-2551. PubMed ID: 28781693
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.
Sanford M
Drugs; 2013 Sep; 73(14):1605-15. PubMed ID: 24057416
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer.
Sui M; Jiao A; Zhai H; Wang Y; Wang Y; Sun D; Li P
Exp Ther Med; 2017 Jul; 14(1):657-663. PubMed ID: 28672982
[TBL] [Abstract][Full Text] [Related]
13. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Kita Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Surg Today; 2022 Dec; 52(12):1721-1730. PubMed ID: 35543754
[TBL] [Abstract][Full Text] [Related]
14. Adding of apatinib and camrelizumab to overcome
Lv H; He Y; Nie C; Du F; Chen X
Front Pharmacol; 2022; 13():1067557. PubMed ID: 36699065
[No Abstract] [Full Text] [Related]
15. Biological Clock Genes are Crucial and Promising Biomarkers for the Therapeutic Targets and Prognostic Assessment in Gastric Cancer.
Tian Y; Xie Y; Bai F; Wang J; Zhang D
J Gastrointest Cancer; 2024 Mar; ():. PubMed ID: 38427147
[TBL] [Abstract][Full Text] [Related]
16. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond.
Kelly CM; Janjigian YY
J Gastrointest Oncol; 2016 Oct; 7(5):750-762. PubMed ID: 27747089
[TBL] [Abstract][Full Text] [Related]
17. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
18. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.
Al-Shamsi HO; Fahmawi Y; Dahbour I; Tabash A; Rogers JE; Mares JE; Blum MA; Estrella J; Matamoros A; Sagebiel T; Devine CE; Badgwell BD; Lin QD; Das P; Ajani JA
J Gastrointest Oncol; 2016 Aug; 7(4):499-505. PubMed ID: 27563438
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive gastric cancer.
Boku N
Gastric Cancer; 2014 Jan; 17(1):1-12. PubMed ID: 23563986
[TBL] [Abstract][Full Text] [Related]
20. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
Kaito A; Kuwata T; Tokunaga M; Shitara K; Sato R; Akimoto T; Kinoshita T
World J Clin Cases; 2019 Aug; 7(15):1964-1977. PubMed ID: 31423428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
